Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 354

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 354
---
     |             |  69,170,622 |   |     | -O    |     |           |             |   |
|                                                                                                                                                                                                        |     |               |             |   |     |                  |             |   |     |             |            |   |     |       |     |             |     485,111 |   |     | -Q    |     |           |             |   |
|                                                                                                                                                                                                        |     |               |             |   |     |                  |             |   |     |             |            |   |     |       |     |             |     316,824 |   |     | -Q    |     |           |             |   |
| Foreign currency translation/Accumulated other comprehensive loss                                                                                                                                      |     |               |    (941,302 | ) |     |                  |       4,207 |   |     |             |          — |   |     |       |     |             |           — |   |     |       |     |           |    (937,095 | ) |
| Total shareholders’ (deficit) equity                                                                                                                                                                   |     |               |  (2,166,533 | ) |     |                  |  (9,268,258 | ) |     |             | 16,844,772 |   |     |       |     |             |   8,894,033 |   |     |       |     |           |  14,625,641 |   |
| Total Liabilities and Shareholders’ (Deficit) Equity                                                                                                                                                   |     | $             |   1,429,636 |   |     | $                |   1,193,458 |   |     | $           |  6,834,341 |   |     |       |     | $           |   6,900,511 |   |     |       |     | $         |  16,357,945 |   |

The accompanying notes are an integral part of these unaudited pro forma condensed combined financial statements.

194

Kadimastem Ltd. & NLS Pharmaceutics Ltd.
Unaudited Pro Forma Condensed Combined Statement of Operations and Other Comprehensive Loss

|                                                                                              |     | For the Six Months Ended June 30, 2024 |            |                  |     |   |            |             |     |   |           |       |     |           |     |   |            |   |